SAN FRANCISCO — In the next few years, publicly traded life sciences companies headquartered in California could collectively need to add hundreds of women to their boards in order to comply with a new state gender-parity law.

That’s going to mean finding women to fill 126 board seats in the sector by the end of 2019. And by the end of 2021, 456 women may need to be recruited to join these boards. All told, across every category of the life sciences sector, at least 85 percent of public California companies will need to add at least one woman to their board by the end of 2021.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy